Aequor’s Novel Molecules Counter Biofilm Associated with Hospital-Acquired Infections
Manufacturers of new antibiotics go bankrupt

700,000 people die from drug-resistant infections – so why do antibiotic companies face bankruptcy? This article was first published in the NZZamSonntag on 26 January 2020 by Birgit Voigt
The Fight Against Superbugs: Properly Incentivising Antimicrobial R&D Is Key

This article was published in Pharma Boardroom on 16 January 2020. Opinion by Greg Frank.
Low Antibiotic Prices Dampen Industry Investment In Vital New Tools To Combat Superbugs – Says AMR Industry Alliance

This article was published in Health Policy Watch 16 January 2020 by Elaine Ruth Fletcher
Industry urges more government action on antibiotic development

This article was published in CIDRAP 16 January 2020. A report by Chris Dall. The level of funding for late-stage research and development of new antibiotics and other products to combat antimicrobial resistance (AMR) is insufficient to meet global health needs, and governments need to step up to the plate, according to an industry report released […]
Industry calls on governments to invest more in antibiotics research

This article was published in Science Business 16 January 2020 by Florin Zubașcu. Alarm over the rise of antimicrobial resistance has prompted an increase in early stage research and led to the discovery of a number of new antibiotics, but for the pharmaceutical industry public investment overall remains at “concerning levels”, and more money needs […]
Peptilogics Receives Qualified Infectious Disease Product Designation from FDA for Lead Compound PLG0206 as a Treatment for Prosthetic Joint Infection
Antimicrobial resistance and vaccines – Life science industry makes the link and drives progress

This Q&A was first published on PharmExec on 20 April, 2018. Interview by Julian Upton. 1. When trying to reduce antimicrobial resistance, how can vaccines help?
Pfizer, ICMR to Establish a Centre in New Delhi to Combat AMR
NZZ – We need a sustainable business model

This interview was first published on NZZ on 24 February 2018. Interview by Birgit Voigt.